Active substance
Propiverine
- SFDA 3
- Health Canada 3
- NHS prices 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Mictonorm | 5 mg | Film-coated tablet · Oral use | 28 Blister | SAR 36.05 | NCE · Prescription | Labatec- Pharma S.A | Valid |
| Mictonorm XL | 30 mg | Modified-release capsule, hard · Oral use | 28 Blister | SAR 150.40 | NCE · Prescription | Labatec- Pharma S.A | Valid |
| Mictonorm XL | 45 mg | Modified-release capsule, soft · Oral use | 28 Blister | SAR 165.45 | NCE · Prescription | Labatec- Pharma S.A | Valid |
Indications — CHI Daman Drug Formulary
URINARY INCONTINENCE AND OVERACTIVE BLADDER
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| MICTORYL | 02460262 | 30 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | DUCHESNAY INC |
| MICTORYL | 02460270 | 45 MG | CAPSULE (EXTENDED-RELEASE) · ORAL | DUCHESNAY INC |
| MICTORYL PEDIATRIC | 02460289 | 5 MG | TABLET · ORAL | DUCHESNAY INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Propiverine 15mg tablets | £36.18 | 56 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Propiverine 30mg modified-release capsules | £24.45 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Propiverine 45mg modified-release capsules | £27.90 | 28 capsule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.